LAG3 and neoplasm: After further combination with anti-LAG-3 mAb and comparing it with dual combination immunotherapy, the triple immunotherapy significantly decreased tumor growth (53 ± 5 mm3 triple immunotherapy vs. 208 ± 23 mm3 STING + αPD-1 dual immunotherapy or 242 ± 17 mm3 STING + αLAG-3 dual immunotherapy or 307 ± 28 mm3 αPD-1 + αLAG-3 dual immunotherapy) (Fig. 5A and B).